vs
Floor & Decor Holdings, Inc.（FND）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Floor & Decor Holdings, Inc.的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs 3.4%，领先9.3%），Revvity同比增速更快（5.9% vs -0.7%），过去两年Revvity的营收复合增速更高（9.0% vs 0.8%）
Floor & Decor Holdings, Inc.是美国多渠道专业零售企业，对外使用Floor & Decor品牌开展业务，创立于2000年，总部位于美国佐治亚州士麦那，主营各类硬质面地板及相关配套配件，线上线下销售渠道全面覆盖。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FND vs RVTY — 直观对比
营收规模更大
FND
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出6.6%
-0.7%
净利率更高
RVTY
高出9.3%
3.4%
两年增速更快
RVTY
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $39.7M | $98.4M |
| 毛利率 | 44.0% | — |
| 营业利润率 | 4.5% | 14.5% |
| 净利率 | 3.4% | 12.7% |
| 营收同比 | -0.7% | 5.9% |
| 净利润同比 | -18.8% | 3.9% |
| 每股收益（稀释后） | $0.37 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNDRVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润FNDRVTY
| Q1 26 | $39.7M | — | ||
| Q4 25 | $39.3M | $98.4M | ||
| Q3 25 | $57.3M | $46.7M | ||
| Q2 25 | $63.2M | $53.9M | ||
| Q1 25 | $48.9M | $42.2M | ||
| Q4 24 | $47.5M | $94.6M | ||
| Q3 24 | $51.7M | $94.4M | ||
| Q2 24 | $56.7M | $55.4M |
毛利率FNDRVTY
| Q1 26 | 44.0% | — | ||
| Q4 25 | 43.5% | — | ||
| Q3 25 | 43.4% | 53.6% | ||
| Q2 25 | 43.9% | 54.5% | ||
| Q1 25 | 43.8% | 56.5% | ||
| Q4 24 | 43.5% | — | ||
| Q3 24 | 43.5% | 56.3% | ||
| Q2 24 | 43.3% | 55.7% |
营业利润率FNDRVTY
| Q1 26 | 4.5% | — | ||
| Q4 25 | 4.6% | 14.5% | ||
| Q3 25 | 6.1% | 11.7% | ||
| Q2 25 | 6.7% | 12.6% | ||
| Q1 25 | 5.5% | 10.9% | ||
| Q4 24 | 5.3% | 16.3% | ||
| Q3 24 | 5.9% | 14.3% | ||
| Q2 24 | 6.3% | 12.4% |
净利率FNDRVTY
| Q1 26 | 3.4% | — | ||
| Q4 25 | 3.5% | 12.7% | ||
| Q3 25 | 4.9% | 6.7% | ||
| Q2 25 | 5.2% | 7.5% | ||
| Q1 25 | 4.2% | 6.4% | ||
| Q4 24 | 4.3% | 13.0% | ||
| Q3 24 | 4.6% | 13.8% | ||
| Q2 24 | 5.0% | 8.0% |
每股收益（稀释后）FNDRVTY
| Q1 26 | $0.37 | — | ||
| Q4 25 | $0.36 | $0.86 | ||
| Q3 25 | $0.53 | $0.40 | ||
| Q2 25 | $0.58 | $0.46 | ||
| Q1 25 | $0.45 | $0.35 | ||
| Q4 24 | $0.44 | $0.77 | ||
| Q3 24 | $0.48 | $0.77 | ||
| Q2 24 | $0.52 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $293.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.5B | $7.3B |
| 总资产 | $5.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FNDRVTY
| Q1 26 | $293.6M | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
股东权益FNDRVTY
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.4B | $7.3B | ||
| Q3 25 | $2.4B | $7.4B | ||
| Q2 25 | $2.3B | $7.6B | ||
| Q1 25 | $2.2B | $7.6B | ||
| Q4 24 | $2.2B | $7.7B | ||
| Q3 24 | $2.1B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B |
总资产FNDRVTY
| Q1 26 | $5.6B | — | ||
| Q4 25 | $5.5B | $12.2B | ||
| Q3 25 | $5.5B | $12.1B | ||
| Q2 25 | $5.4B | $12.4B | ||
| Q1 25 | $5.4B | $12.4B | ||
| Q4 24 | $5.1B | $12.4B | ||
| Q3 24 | $4.9B | $12.8B | ||
| Q2 24 | $4.8B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $109.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 2.75× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FNDRVTY
| Q1 26 | $109.2M | — | ||
| Q4 25 | $124.1M | $182.0M | ||
| Q3 25 | $102.5M | $138.5M | ||
| Q2 25 | $84.1M | $134.3M | ||
| Q1 25 | $71.2M | $128.2M | ||
| Q4 24 | $101.4M | $174.2M | ||
| Q3 24 | $160.3M | $147.9M | ||
| Q2 24 | $194.0M | $158.6M |
自由现金流FNDRVTY
| Q1 26 | — | — | ||
| Q4 25 | $45.1M | $161.8M | ||
| Q3 25 | $24.5M | $120.0M | ||
| Q2 25 | $-10.0M | $115.5M | ||
| Q1 25 | $4.4M | $112.2M | ||
| Q4 24 | $3.9M | $149.8M | ||
| Q3 24 | $36.5M | $125.6M | ||
| Q2 24 | $80.0M | $136.6M |
自由现金流率FNDRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 21.0% | ||
| Q3 25 | 2.1% | 17.2% | ||
| Q2 25 | -0.8% | 16.0% | ||
| Q1 25 | 0.4% | 16.9% | ||
| Q4 24 | 0.4% | 20.5% | ||
| Q3 24 | 3.3% | 18.4% | ||
| Q2 24 | 7.1% | 19.7% |
资本支出强度FNDRVTY
| Q1 26 | — | — | ||
| Q4 25 | 7.0% | 2.6% | ||
| Q3 25 | 6.6% | 2.6% | ||
| Q2 25 | 7.8% | 2.6% | ||
| Q1 25 | 5.7% | 2.4% | ||
| Q4 24 | 8.8% | 3.4% | ||
| Q3 24 | 11.1% | 3.3% | ||
| Q2 24 | 10.1% | 3.2% |
现金转化率FNDRVTY
| Q1 26 | 2.75× | — | ||
| Q4 25 | 3.15× | 1.85× | ||
| Q3 25 | 1.79× | 2.97× | ||
| Q2 25 | 1.33× | 2.49× | ||
| Q1 25 | 1.46× | 3.03× | ||
| Q4 24 | 2.14× | 1.84× | ||
| Q3 24 | 3.10× | 1.57× | ||
| Q2 24 | 3.42× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FND
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
